Practical recommendation for treatment of patients with colon cancer during covid-19 pandemic

Федянин М. Ю.

Статья

Ведение больных раком толстой кишки в условиях эпидемии коронавирусной инфекции

Федянин М. Ю.,

2020

https://doi.org/10.21518/2079-701X-2020-9-213-224

Ограничение оказания онкологический помощи в условиях эпидемии наблюдается в большинстве стран мира. Это связано, прежде всего, с появившейся в первых небольших публикациях из Китая информацией о повышенной восприимчивости онкологических пациентов и повышенном риске тяжелого течения новой инфекции, что привело к отмене плановых операций, отсрочке начала адъювантной терапии, переводу консультаций специалистов в формат телемедицины. Свой вклад внесли и случаи заболевания медицинского персонала, и перепрофилирование клинических подразделений и целых клиник, которые ранее оказывали помощь онкологическим больным, на лечение пациентов с COVID-19. Это все породило чувство страха перед неизвестностью у онкологов и больных. В данной статье представлен опыт лечения вирусной инфекции у онкологических больных разных стран. Рассмотрены рекомендации противоопухолевых обществ различных стран мира по оказанию терапии онкологическим пациентам. На примере рака толстой кишки рассмотрены подходы к лечению, которые в условиях повышенной эпидемической опасности позволят проводить нашим пациентам полноценное противоопухолевое лечение. Обоснована необходимость проведения короткого курса лучевой терапии совместно с химиотерапией на предоперационном этапе лечения местнораспространенного рака прямой кишки, уменьшения числа курсов адъювантной химиотерапии при 3-й стадии рака ободочной кишки. Определены приоритеты в выборе первой и последующих линий терапии метастатических опухолей; отсутствие необходимости удаления бессимптомной первичной опухоли при неоперабельных метастазах; возможности иммунотерапии при опухолях с микросателлитной нестабильностью высокого уровня; комбинации таргетной терапии при опухолях с мутацией в гене BRAF.

Цитирование

Список литературы

1. Zheng R.S., Sun K.X., Zhang S.W., Zeng H.M., Zou X.N., Chen R. et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41:19–28. (In Chinese) doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.

2. Liang W., Guan W., Chen R., Wang W., Li J., Xu K. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi: 10.1016/S1470-2045(20)30096-6.

3. Kamboj M., Sepkowitz K.A. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10(6):589–597. doi: 10.1016/S1470-2045(09)70069-5.

4. Yu J., Ouyang W., Chua M.L.K., Xie C. SARS-CoV-2 Transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;e200980. doi: 10.1001/jamaoncol.2020.0980.

5. Zhang L., Zhu F., Xie L., Wang C., Wang J., Chen R. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. doi: 10.1016/j.annonc.2020.03.296.

6. Ma J., Yin J., Qian Y., Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center’s retrospective study. J Infect. 2020;S0163-4453(20)30214-0. doi: 10.1016/j.jinf.2020.04.006.

7. Lou E., Beg S., Bergsland E., Eng C., Khorana A., Kopetz S. et al. Modifying practices in GI oncology in the face of COVID-19: recommendations from expert oncologists on minimizing patient risk. JCO Oncol Pract. 2020;OP2000239. doi: 10.1200/OP.20.00239

8. Marshall J.L., Yarden R.I., Weinberg B.A. Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit. Colorectal Cancer. 2020;0(0):10.2217/crc-2020-0010. doi: 10.2217/crc-2020-0010.

9. Omarini C., Maur M., Luppi G., Narni F., Luppi M., Dominic M. et al. Cancer treatment during COVID-19 pandemic: do not postpone, do it! Eur J Cancer. 2020;133:29–32. doi: 10.1016/j.ejca.2020.04.034.

10. Garassino M.C. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID19 in patients with thoracic malignancies. AACR 2020. Available at: https://www.abstractsonline.com/pp8/#!/9045/presentation/10927.

11. Horn L., Whisenant J.G., Torri V., Huang L.C., Trama A., Paz-Ares L.G. et al. Thoracic cancers international COVID-19 collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival. J Clin Oncol 2020;38(18):LBA111. doi: 10.1200/JCO.2020.38.18_suppl.LBA111.

12. Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi: 10.1158/2159-8290.CD-20-0422.

13. Barlesi F., Foulon S., Bayle A. Outcome of cancer patients infected with COVID19, including toxicity of cancer treatments. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27–28, 2020. Plenary session.

14. Ascierto P.A. Experience in using oncology drugs in patients with COVID. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27–28, 2020. Plenary session.

15. Lee L.Y.W., Cazier J.B., Starkey T., Turnbull C.D. UK Coronavirus Cancer Monitoring Project Team, Kerr R., Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–1926. doi: 10.1016/S0140-6736(20)31173-9

16. Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. doi: 10.1016/S0140-6736(20)31187-9.

17. Miyashita H., Mikami T., Chopra N., Yamada T., Chernyavsky S., Rizk D., Cruz C. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;S0923-7534(20)39303-0. doi: 10.1016/j.annonc.2020.04.006.

18. Sharpless N.E. Ensuring cancer research progress during a global pandemic. 2020 ASCO Virtual Scientific Program. Available at: https://meetinglibrary.asco.org/record/191996/video.

19. Dinmohamed A.G., Visser O., Verhoeven R.H.A., Louwman M.W.J., van Nederveen F.H., Willems S.M. et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–751. doi: 10.1016/S1470-2045(20)30265-5.

20. Nagar H., Formenti S.C. Cancer and COVID-19 – potentially deleterious effects of delaying radiotherapy. Nat Rev Clin Oncol. 2020;17(6):332–334. doi: 10.1038/s41571-020-0375-1.

21. Folkesson J., Birgisson H., Pahlman L., Cedermark B., Glimelius B., Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. Clin Oncol. 2005;23(24):5644–5650. doi: 10.1200/JCO.2005.08.144.

22. van Gijn W., Marijnen C.A.M., Nagtegaal I.D., Kranenbarg E.M.K., Putter H., Wiggers T. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575– 582. doi: 10.1016/S1470-2045(11)70097-3.

23. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–1223. doi: 10.1002/bjs.5506.

24. Ngan S.Y., Burmeister B., Fisher R.J., Solomon M., Goldstein D., Joseph D. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol. 2012;30(31):3827–3833. doi: 10.1200/JCO.2012.42.9597.

25. Francois Y., Nemoz C.J., Baulieux J., Vignal J., Grandjean J.P., Partensky C. et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396. doi: 10.1200/JCO.1999.17.8.2396.

26. Probst C.P., Becerra A.Z., Aquina C.T., Tejani M.A., Wexner S.D., GarciaAguilar J. et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430–440. doi: 10.1016/j.jamcollsurg.2015.04.010.

27. Lee S.W., Lee J.H., Lee I.K., Oh S.T., Kim D.Y., Kim T.H. et al. The impact of surgical timing on pathologic tumor response after short course and long course preoperative chemoradiation for locally advanced rectal adenocarcinoma. Cancer Res Treat. 2018;50(3):1039–1050. doi: 10.4143/crt.2017.252.

28. On J., Aly E.H. “Watch and wait” in rectal cancer: summary of the current evidence. Int J Colorectal Dis. 2018;33(9):1159–1168. doi: 10.1007/s00384-018-3116-5.

29. Kwak Y.K., Kim K., Lee J.H., Kim S.H., Cho H.M., Kim D.Y. et al. Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: A multi-institutional study for optimal surgical timing in rectal cancer. Radiother Oncol. 2016;119(3):512–518. doi: 10.1016/j.radonc.2016.03.017.

30. Lefèvre J.H., Mineur L., Cachanado M., Denost Q., Rouanet P., de Chaisemartin C. et al. Does a longer waiting period after Neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer? Three years’ follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg. 2019;270(5):747–754. doi: 10.1097/SLA.0000000000003530.

31. Garcia-Aguilar J., Chow O.S., Smith D.D., Marcet J.E., Cataldo P.A., Varma M.G. et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–966. doi: 10.1016/S1470-2045(15)00004-2.

32. Fokas E., Allgäuer M., Polat B., Klautke G., Grabenbauer G.G., Fietkau R. et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212–3222. doi: 10.1200/JCO.19.00308.

33. Garcia-Aguilar J., Patil S., Kim J.K., Yuval J.B., Thompson H., Verheij F. et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol. 2020;38(15):4008. doi: 10.1200/JCO.2020.38.15_suppl.4008.

34. Bujko K., Wyrwicz L., Rutkowski A., Malinowska M., Pietrzak L., Kryński J. et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–842. doi: 10.1093/annonc/mdw062.

35. Ciseł B., Pietrzak L., Michalski W., Wyrwicz L., Rutkowski A., Kosakowska E. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–1303. doi: 10.1093/annonc/mdz186.

36. Hospers G., Bahadoer R.R., Dijkstra E.A., van Etten B., Marijnen C., Putter H. et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. J Clin Oncol. 2020;38(15):4006. doi: 10.1200/JCO.2020.38.15_suppl.4006.

37. Fernandez L.M., Figueiredo N., Beets G., Valk M.V.D., Bahadoer R., Hilling D. et al. Conditional survival of patients with rectal cancer undergoing Watch and Wait: The risk of recurrence over time. J Clin Oncol. 2020;38(4):30. doi: 10.1200/JCO.2020.38.4_suppl.30.

38. Deng Y., Chi P., Lan P., Wang L., Chen W., Cui L. et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37(34):3223–3233. doi: 10.1200/JCO.18.02309.

39. Seymour M.T., Morton D. FOxTROT Collaborative Group. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 2019;37(15):3504. doi: 10.1200/JCO.2019.37.15_suppl.3504.

40. Seligmann J.F. FOxTROT Collaborative Group. FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC). J Clin Oncol. 2020;38(15_ suppl):4013. doi: 10.1200/JCO.2020.38.15_suppl.4013.

41. Grothey A., Sobrero A.F., Shields A.F., Yoshino T., Paul J., Taie J. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177–1188. doi: 10.1056/NEJMoa1713709.

42. Sobrero A.F., Andre T., Meyerhardt J.A., Grothey A., Iveson T., Yoshino T. et al. Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. J Clin Oncol 2020;38(15):4004. doi: 10.1200/JCO.2020.38.15_suppl.4004.

43. Iveson T., Sobrero A.F., Yoshino T., Sougklakos I., Ou F.S., Meyers J.P. et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). J Clin Oncol. 2019;37(15):3501. doi: 10.1200/JCO.2019.37.15_suppl.3501.

44. Федянин М.Ю. Адъювантная терапия больных раком толстой кишки II стадии — трудное решение для химиотерапевта. Злокачественные опухоли. 2019;9(3s1):15–22. doi: 10.18027/2224-5057-2019-9-3s1-15-22. Fedyanin M.Yu. Adjuvant therapy for patients with colon cancer with stage II – complex decision for medical oncologist. Zlokachestvennye opukholi = Malignant tumors. 2019;9(3s1):15–22. (In Russ.) doi: 10.18027/2224-5057-2019-9-3s1-15-22.

45. Biagi J.J., Raphael M., Mackillop W., Kong W., King D., Booth C. The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. Journal of Clinical Oncology. 2011;29:(4_suppl 4):364. doi: 10.1200/jco.2011.29.4_suppl.364.

46. Petrelli F., Zaniboni A., Ghidini A., Ghidini M., Turati L., Pizzo C. et al. Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer. A systematic review and meta-analysis. Cancers (Basel). 2019;11(4):550. doi: 10.3390/cancers11040550.

47. Jafari A., Dadkhahfar S., Perseh S. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. Critical Reviews in Oncology/Hematology. 2020;151:102982. doi: 10.1016/j.critrevonc.2020.102982.

48. Lorenzo G.D., Trolio R.D., Kozlakidis Z., Busto G., Ingenito C., Buonerba L. et al. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature [published online ahead of print, 2020 May 21]. Crit Rev Oncol Hematol. 2020;152:102991. doi: 10.1016/j.critrevonc.2020.102991.

49. Kanemitsu Y., Shitara K., Mizusawa J., Hamaguchi T., Shida D., Komori K. et al. A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS). J Clin Oncol. 2020;38(4):7. doi: 10.1200/JCO.2020.38.4_suppl.7.

50. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P. et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–1215. doi: 10.1016/S1470-2045(13)70447-9.

51. Bridgewater J.A., Pugh S.A., Maishman T., Eminton Z., Mellor J., Whitehead A. et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398–411. doi: 10.1016/S1470-2045(19)30798-3.

52. Takakura Y., Shinozaki K., Ikeda S., Egi H., Hirata Y., Shimomura M. et al. Pre- versus postoperative CAPOX plus bevacizumab (CAPOX-Bev) for resectable liver metastases from colorectal cancer (CLM): A randomized phase II/III trial (HiSCO- 01). J Clin Oncol. 2020;38(15):4021. doi: 10.1200/JCO.2020.38.15_suppl.4021.

53. Holch J.W., Ricard I., Stintzing S., Modest D.P., Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98. doi: 10.1016/j.ejca.2016.10.007.

54. Maughan T.S., Adams R.A., Smith C.G., Meade A.M., Seymour M.T., Wilson R.H. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–2114. doi: 10.1016/S0140-6736(11)60613-2.

55. Guren T.K., Thomsen M., Kure E.H., Sorbye H., Glimelius B., Pfeiffer P. et al. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. Br J Cancer. 2017;116(10):1271–1278. doi: 10.1038/bjc.2017.93.

56. Soda H., Maeda H., Hasegawa J., Takahashi T., Hazama S., Fukunaga M. et al. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC Cancer. 2015;15:695. doi: 10.1186/s12885-015-1685-z.

57. Tabernero J., Ciardiello F., Rivera F., Rodriguez-Braun E., Ramos F.J., Martinelli E. et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/ pharmacodynamic phase I dose-escalation study. Ann Oncol. 2010;21(7):1537–1545. doi: 10.1093/annonc/mdp549.

58. Pescott C., Batech M., Boutmy E., Ronga P., Lamy F.X. Overall survival of cetuximab administered every two weeks versus weekly in real-world data of U.S. patients with metastatic colorectal cancer. J Clin Oncol. 2020;38(4):23. doi: 10.1200/JCO.2020.38.4_suppl.23.

59. Basilio A., Shah A., Sommerer K., Chehab S., Bottiglieri S.M., Imanirad I. Impact of empirically eliminating 5-fluorouracil (5-FU) bolus and leucovorin (LV) in patients with metastatic colorectal cancer (mCRC) receiving first-line treatment with mFOLFOX6. J Clin Oncol. 2020;38(1):4022. doi: 10.1200/JCO.2020.38.15_suppl.4022.

60. Pinter T., Klippe Z., Cesas A., Croitoru A., Decaestecker J., Gibbs P. et al. A phase III, randomized, double-blind, placebo-controlled trial of Pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advanced or metastatic colorectal cancer: final results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clin Colorectal Cancer. 2017;16(2):103–114.e3. doi: 10.1016/j.clcc.2016.08.008.

61. Федянин М.Ю., Полянская Е.М., Покатаев И.А., Трякин А.А., Сехина О.В., Чекини Д.А. и др. Применение комбинации FOLFOXiRi у больных раком толстой кишки с изолированным нерезектабельным метастатическим поражением печени: проспективное нерандомизированное одноцентровое исследование II фазы. Тазовая хирургия и онкология. 2019;9(4):21–31. doi: 10.17650/2686-9594-2019-9-4-21-31. Fedyanin M.Y., Polyanskaya E.M., Pokataev I.A., Tryakin A.A., Sekhina O.V. et al. FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study. Tazovaya khirurgiya i onkologiya = Pelvic Surgery and Oncology. 2019;9(4):21–31. (In Russ.) doi: 10.17650/2686-9594-2019-9-4-21-31.

62. Волкова М.И., Гладков О.А., Деньгина Н.В., Карасева В.В., Митин Т., Моисеенко В.М. и др. Практические рекомендации Российского общества клинической онкологии по оказанию онкологической помощи в условиях пандемии COVID19. Режим доступа: https://rosoncoweb.ru/ standarts/COVID-19. Volkova M.I., Gladkov O.A., Dengina N.V., Karaseva V.V., Mitin T., Moiseenko V.M. et al. Practical guidelines of the Russian Society of Clinical Oncology for cancer treatment in the COVID19 pandemic. (In Russ.) Available at: https://rosoncoweb.ru/standarts/COVID-19.

63. Marmorino F., Rossini D., Lonardi S. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Ann Oncol. 2019;30(12):1969–1977. doi: 10.1093/annonc/mdz403.

64. Pectasides D., Papaxoinis G., Kalogeras K.T., Eleftheraki A.G., Xanthakis I., Makatsori T. et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer. 2012;12:271. doi: 10.1186/1471-2407-12-271.

65. Xu R.H., Muro K., Morita S., Iwasa S., Han S.W., Wang W. et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018;19(5):660–671. doi: 10.1016/S1470-2045(18)30140-2.

66. Fukui T., Suzuki K., Ichida K., Takayama Y., Kakizawa N., Muto Y. et al. Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer. Oncol Lett. 2017;13(6):4947–4952. doi: 10.3892/ol.2017.6100.

67. Guo W., Zhang X., Wang Y., Zhang W., Liu X., Shen W. et al. FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study. J Clin Oncol. 2020;38(15):4038. doi: 10.1200/JCO.2020.38.15_suppl.4038.

68. Cremolini C., Antoniotti C., Stein A., Bendell J.C., Gruenberger T., Masi G. et al. FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials. J Clin Oncol. 2020;38(15):4015. doi: 10.1200/JCO.2020.38.15_suppl.4015.

69. Kopetz S., Grothey A., Cutsem E.V., Yaeger R., Wasan H.S., Yoshino T. et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. 2020;38:(15):4001. doi: 10.1200/JCO.2020.38.15_suppl.4001.

70. Andre T., Shiu K.K., Kim T.W., Jensen B.V., Jensen L.H., Punt C.J.A. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/ mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. J Clin Oncol. 2020;38(18):LBA4. doi: 10.1200/JCO.2020.38.18_suppl.LBA4.

71. Lala M. Abstract CT042. Presented at: AACR Annual Meeting; April 27–28, 2020 (virtual meeting).

72. Long G.V., Tykodi S.S., Schneider J.G., Garbe C., Gravis G., Rashford M. et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol.;29(11):2208–2213. doi: 10.1093/annonc/mdy408.

73. Pietrantonio F., Morano F., Niger M., Corallo S., Antista M., Raimondi A. et al. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan [published online ahead of print, 2020 May 23]. Clin Colorectal Cancer. 2020;S1533-0028(20)30077-3. doi: 10.1016/j.clcc.2020.05.004.

Источник

Версии

1. Version of Record от 2020-07-29

Метаданные

Об авторах

Федянин М. Ю.
Национальный медицинский онкологический центр им. Н.Н. Блохина; Российский университет дружбы народов

Предметная рубрика

COVID-19

Название журнала

Meditsinskiy sovet = Medical Council

Страницы

213-224

Тип документа

journal article

Тип лицензии Creative Commons

CC BY

Правовой статус документа

Свободная лицензия

Источник

elpub

Поиск по репозиторию

Статья

Ведение больных раком толстой кишки в условиях эпидемии коронавирусной инфекции

Похожие публикации

Источник

Версии

Метаданные